CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy

Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara, Robert T. O'Donnell

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely expressed in lung cancer cells. In characterizing the antitumor activity of an established anti-CD22 monoclonal antibody (mAb), HB22.7, we showed CD22 expression by multiple approaches in various lung cancer subtypes, including 7 of 8 cell lines and a panel of primary patient specimens. HB22.7 displayed in vitro and in vivo cytotoxicity against CD22-positive human lung cancer cells and tumor xenografts. In a model of metastatic lung cancer, HB22.7 inhibited the development of pulmonary metastasis and extended overall survival. The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis. Our work suggests that anti- CD22 mAbs may be useful for targeted therapy of lung cancer, a malignancy that has few tumor-specific targets.

Original languageEnglish (US)
Pages (from-to)5556-5565
Number of pages10
JournalCancer Research
Volume72
Issue number21
DOIs
StatePublished - Nov 1 2012

Fingerprint

Sialic Acid Binding Ig-like Lectin 2
Lung Neoplasms
Antibodies
Therapeutics
Neoplasm Metastasis
Neoplasms
Heterografts
Cell Adhesion
Cell Survival
Carcinogenesis
B-Lymphocytes
Monoclonal Antibodies
Cell Line
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. / Tuscano, Joseph M.; Kato, Jason; Pearson, David; Xiong, Chengyi; Newell, Laura; Ma, Yunpeng; Gandara, David R.; O'Donnell, Robert T.

In: Cancer Research, Vol. 72, No. 21, 01.11.2012, p. 5556-5565.

Research output: Contribution to journalArticle

Tuscano, JM, Kato, J, Pearson, D, Xiong, C, Newell, L, Ma, Y, Gandara, DR & O'Donnell, RT 2012, 'CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy', Cancer Research, vol. 72, no. 21, pp. 5556-5565. https://doi.org/10.1158/0008-5472.CAN-12-0173
Tuscano, Joseph M. ; Kato, Jason ; Pearson, David ; Xiong, Chengyi ; Newell, Laura ; Ma, Yunpeng ; Gandara, David R. ; O'Donnell, Robert T. / CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. In: Cancer Research. 2012 ; Vol. 72, No. 21. pp. 5556-5565.
@article{8de62569177746b695b1f46bd3fc6f58,
title = "CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy",
abstract = "Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely expressed in lung cancer cells. In characterizing the antitumor activity of an established anti-CD22 monoclonal antibody (mAb), HB22.7, we showed CD22 expression by multiple approaches in various lung cancer subtypes, including 7 of 8 cell lines and a panel of primary patient specimens. HB22.7 displayed in vitro and in vivo cytotoxicity against CD22-positive human lung cancer cells and tumor xenografts. In a model of metastatic lung cancer, HB22.7 inhibited the development of pulmonary metastasis and extended overall survival. The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis. Our work suggests that anti- CD22 mAbs may be useful for targeted therapy of lung cancer, a malignancy that has few tumor-specific targets.",
author = "Tuscano, {Joseph M.} and Jason Kato and David Pearson and Chengyi Xiong and Laura Newell and Yunpeng Ma and Gandara, {David R.} and O'Donnell, {Robert T.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-12-0173",
language = "English (US)",
volume = "72",
pages = "5556--5565",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy

AU - Tuscano, Joseph M.

AU - Kato, Jason

AU - Pearson, David

AU - Xiong, Chengyi

AU - Newell, Laura

AU - Ma, Yunpeng

AU - Gandara, David R.

AU - O'Donnell, Robert T.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely expressed in lung cancer cells. In characterizing the antitumor activity of an established anti-CD22 monoclonal antibody (mAb), HB22.7, we showed CD22 expression by multiple approaches in various lung cancer subtypes, including 7 of 8 cell lines and a panel of primary patient specimens. HB22.7 displayed in vitro and in vivo cytotoxicity against CD22-positive human lung cancer cells and tumor xenografts. In a model of metastatic lung cancer, HB22.7 inhibited the development of pulmonary metastasis and extended overall survival. The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis. Our work suggests that anti- CD22 mAbs may be useful for targeted therapy of lung cancer, a malignancy that has few tumor-specific targets.

AB - Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely expressed in lung cancer cells. In characterizing the antitumor activity of an established anti-CD22 monoclonal antibody (mAb), HB22.7, we showed CD22 expression by multiple approaches in various lung cancer subtypes, including 7 of 8 cell lines and a panel of primary patient specimens. HB22.7 displayed in vitro and in vivo cytotoxicity against CD22-positive human lung cancer cells and tumor xenografts. In a model of metastatic lung cancer, HB22.7 inhibited the development of pulmonary metastasis and extended overall survival. The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis. Our work suggests that anti- CD22 mAbs may be useful for targeted therapy of lung cancer, a malignancy that has few tumor-specific targets.

UR - http://www.scopus.com/inward/record.url?scp=84868262326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868262326&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0173

DO - 10.1158/0008-5472.CAN-12-0173

M3 - Article

VL - 72

SP - 5556

EP - 5565

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -